Skip to content

Study on the Effect of Filters on Discomfort Glare on Healthy Adults

Etude De L'Effet De Filtres Sur L'Eblouissement D'Inconfort

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06701981
Acronym
PREVIS
Enrollment
60
Registered
2024-11-22
Start date
2024-12-02
Completion date
2025-03-31
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glare

Keywords

glare, filter

Brief summary

The goal of this clinical trial is to evaluate the glare protection provided by two filters compared to no filter. Using the Lumiz 100™ device (a headset with gradually increasing light), participants will measure their discomfort thresholds under three different conditions (one per filter). Each measurement will be repeated three times. The study requires a single visit of 2 hours for each participant. Glare protection will be quantified by comparing discomfort thresholds across the no-filter condition and the two studied filters.

Interventions

OTHERFilter comparison

Three filters will be compared on light discomfort thresholds using the Lumiz 100™ device

Sponsors

Essilor International
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* A willing person, fluent in French, inclined to follow protocol, capable of reading and understanding the information form, and able to give their free and informed consent. * Beneficiary of the French Social Security system * Aged 18 to 65 years * No or moderate ocular correction (Spherical prescription for distance vision: in the range \[-8.00 to +6.00 D\]\* (negative cylinder) for each eye; Cylindrical prescription for distance vision: in the range \[0 to -4.00 D\] for each eye; Anisometropia ≤ 2.00 D on the equivalent sphere) * Correct vision with prescription glasses (Corrected visual acuity +0.10 logMAR or better (distance vision / high contrast / photopic luminance) * Regular user of sunglasses at least in bright light conditions

Exclusion criteria

* Age \< 18 years (i.e., no minors in accordance with Article L1121-7 of the Public Health Code of Code de Santé Publique) * Pregnant, parturient, or breastfeeding women (Article L1121-5 of the Public Health Code of Code de Santé Publique) * Persons deprived of liberty by judicial or administrative decision and persons hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8, and persons admitted to a health or social institution for purposes other than research * Adults incapable or unable to express their consent (Article L1121-8 of the Public Health Code of Code de Santé Publique) * Participant in the exclusion period of another biomedical research study * Participant who cannot be contacted in case of emergency * All categories of persons particularly protected under French law are excluded from this research (Articles L1121-5 to L1121-9 of the Public Health Code) * Employees at the Institut des Sciences de la Vision or EssilorLuxottica * Ocular pathology that may affect vision (e.g., glaucoma involving visual field loss, maculopathy involving visual acuity loss, or retinitis pigmentosa causing significant discomfort in poorly or overly lit environments) * Neurological deficit, including a history of epileptic pathology or regular or severe migraines * Ocular surgery affecting vision (e.g., refractive surgery, cataract surgery, or iridectomy) * Ocular or head trauma

Design outcomes

Primary

MeasureTime frameDescription
Light discomfort thresholds2 hoursAmount of light (in lux) that produce a defined discomfort level (just perceptible or really disturbing)

Countries

France

Contacts

Primary ContactPascale Lacan, PhD
lacanp@essilor.fr+33155964816

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026